For decades, drugging the ‘undruggable’ was thought to require luck rather than logic. Today, AI is transforming serendipity into strategy by enabling rational, data-driven approaches to previously inaccessible targets.

AI in drug discovery is evolving fast. Join the experts behind today’s real progress as they share what works, what doesn’t and what you need to know next.

Researchers at the University of Cincinnati are developing an immune-stimulating wafer to be used after brain tumour surgery, aiming to overcome long-standing barriers in the treatment of glioblastoma and inform new personalised therapies.

Scientists have developed enhanced NK cell therapy that could help people with HIV control the virus without lifelong antiretroviral treatment.

New research has demonstrated how a common virus may trigger the immune attack that leads to multiple sclerosis, providing a deeper look into a disease that affects nearly one million people in the US.

Scientists have developed a lab-made antibody that targets a sugar found only on bacterial cells, successfully clearing deadly, drug-resistant infections in mice.

Addex Therapeutics has published new research showing that targeting the mGlu7 receptor with a negative allosteric modulator can disrupt fear memory reconsolidation, offering a potential new approach to treating anxiety and PTSD.

New preclinical research shows that psilocybin’s behavioural and inflammatory effects vary with metabolic state and exercise, highlighting key biological variables that could inform drug discovery, target selection and patient stratification in psychedelic therapeutics.

Early drug discovery has no shortage of genomic data, but confidence remains scarce. This report examines how CRISPR, functional genomics and human-relevant models are being applied to determine which signals matter, how they influence disease biology and which targets and strategies are worth pursuing.

Automation now plays a central role in discovery. From self-driving laboratories to real-time bioprocessing, this report explores how data-driven systems improve reproducibility, speed decisions and make scale achievable across research and development.

Biomarkers are redefining how precision therapies are discovered, validated and delivered. This exclusive expert-led report reveals how leading teams are using biomarker science to drive faster insights, cleaner data and more targeted treatments – from discovery to diagnostics.

Explore how artificial intelligence (AI), biomarkers, and innovative trial technologies are creating a more efficient, data-driven future for drug discovery. From better patient selection to smarter trial design, see how clinical research is evolving to deliver new therapies faster.